Patricia K. Coyle, MD Professor and Vice Chair Clinical Affairs Department of Neurology Director, MS Comprehensive Care Center Stony Brook University SUNY Stony Brook, NY
Fred D. Lublin, MD, FAAN Saunders Family Professor of Neurology Icahn School of Medicine at Mt. Sinai Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis Mount Sinai Medical Center New York, NY
AMA PRA Category 1 Credit™
THIS ACTIVITY WAS ORIGINALLY PRESENTED AS A LIVE WEBCONFERENCE ON AUGUST 12, 2013. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE LIVE EVENT, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ENDURING ARCHIVE.
An estimated 350,000 to 500,000 people in the United States are currently diagnosed with multiple sclerosis (MS), a chronic neurologic disorder with potential for substantial negative impact on quality of life. A wide variety of neurological symptoms can occur with MS, including tingling and numbness, loss of balance, weakness in one or more limbs, and vision problems. Treatment is focused on returning function after an attack, preventing new attacks, and preventing disability.
The heterogeneity of the pathogenesis of MS and wide variation in the clinical course for each patient make management of MS challenging for clinicians. Neurologists have an opportunity to improve the treatment of MS by expanding their ability to individualize treatment decisions for each patient at each stage of MS. This activity offered participants the opportunity to ask questions of two leading MS experts. Program Developer/Facilitator
. Target Audience
The educational design of this activity addresses the needs of neurologists, neurological nurses, and other health care clinicians involved or interested in the treatment of patients with multiple sclerosis.
In order to obtain credit, participants must complete the activity in full as well as the Post-Test and Evaluation. Learning Objectives
Upon completion of this educational activity, the participant should be able to:
Review advances in markers of disease activity and imaging technologies to diagnose and monitor MS disease progression.
Summarize current and emerging treatment approaches to manage symptoms throughout the disease course commonly experienced by patients with MS.
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Patricia K. Coyle, MD, discloses that she is a consultant to Genzyme/Sanofi and Novartis; and has received honoraria from Accordant, Acorda, Bayer, Biogen, EMD Serono, Roche, and Teva.
Fred D. Lublin, MD, FAAN, discloses that he has received research funding from Acorda Therapeutics, Inc.; Biogen Idec; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.; Genzyme; Sanofi; Celgene; NIH; and NMSS. He has consulted for Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Novartis; Pfizer; Teva Neuroscience; Actelion; Sanofi-Aventis; Acorda; Questcor; Roche, Genentech; Celgene; Johnson & Johnson; Revalesio; Coronado Bioscience, Genzyme, MedImmune; Bristol-Myers Squibb, Xenoport, and Receptos. He also owns stock in Cognition Pharmaceuticals, Inc.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Ashley Marostica, RN, MSN: Nothing to disclose
Amanda Glazar, PhD: Nothing to disclose
Kathleen Hines: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and MCM Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and MCM Education. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
This activity is jointly sponsored by Global Education Group and MCM Education.
Commercial Support Statements
This activity is supported by an independent educational grant from Novartis Corporation.
©2013, MCM Education. All rights reserved. This activity is designed to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. None of the content may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this webconference are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Global Education Group, or Novartis. Any medications or other diagnostic or treatment procedures presented by the program faculty should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.